Cell cycle deregulation in breast cancer: Insurmountable chemoresistance or Achilles' heel?

Advances in Experimental Medicine and Biology

Volumn 608, Issue , 2007, Pages 52-69

  Lambert, Laura ^a   Keyomarsi, Khandan ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIN E;

BREAST TUMOR; CELL CYCLE; DRUG EFFECT; DRUG RESISTANCE; FEMALE; HUMAN; METABOLISM; REVIEW;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL CYCLE; CYCLIN E; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS;

EID: 38449111862     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-0-387-74039-3_4     Document Type: Review

References (200)

1. Keyomarsi K, O'Leary N, Molnar G et al. Cyclin E, a potential prognostic marker for breast cancer. Cancer Res 1994;54(2):380-385.
2. Keyomarsi K, Tucker SL, Buchholz TA et al. Cyclin E and survival in patients with breast cancer. N Engl J Med 2002;347(20):1566-1575.
3. Pardee AB. G1 events and regulation of cell proliferation. Science 1989;246(4930):603-608.
4. Porter DC, Zhang N, Danes C et al. Tumor-specific proteolytic processing of cyclin E generates hyperactive lower-molecular-weight forms. Mol Cell Biol 2001;21(18):6254-6269.
5. Tamoxifen for early breast cancer: An overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998;351(9114):1451- 1467.
6. Polychemotherapy for early breast cancer: An overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998;352(9132):930-942.
7. Berns K, Hijmans EM, Bernards R. Repression of c-Myc responsive genes in cycling cells causes G1 arrest through reduction of cyclin E/CDK2 kinase activity. Oncogene 1997;15(11):1347-1356.
8. Berns K, Martins C, Dannenberg JH et al. p27kip1-independent cell cycle regulation by MYC. Oncogene 2000;19(42):4822-4827.
9. Beier R, Burgin A, Kiermaier A et al. Induction of cyclin E-cdk2 kinase activity, E2F-dependent transcription and cell growth by Myc are genetically separable events. Embo J 2000;19(21):5813-5823.
10. Roussel MF, Theodoras AM, Pagano M et al. Rescue of defective mitogenic signaling by D-type cyclins. Proc Natl Acad Sci USA 1995;92(15):6837-6841.
11. Leone G, DeGregori J, Sears R et al. Myc and Ras collaborate in inducing accumulation of active cyclin E/Cdk2 and E2F. Nature 1997;387(6631):422-426.
12. Santoni-Rugiu E, Falck J, Mailand N et al. Involvement of Myc activity in a G (1)/S-promoting mechanism parallel to the pRb/E2F pathway. Mol Cell Biol 2000;20(10):3497-3509.
13. Bartek J, Bartkova J, Lukas J. The retinoblastoma protein pathway and the restriction point. Curr Opin Cell Biol 1996;8(6):805-814.
14. Sherr CJ, Roberts JM. CDK inhibitors: Positive and negative regulators of G1-phase progression. Genes Dev 1999;13(12):1501-1512.
15. Muller-Tidow C, Metzger R, Kugler K et al. Cyclin E is the only cyclin-dependent kinase 2-associated cyclin that predicts metastasis and survival in early stage nonsmall cell lung cancer. Cancer Res 2001;61(2):647-653.
16. Porter PL, Malone KE, Heagerty PJ et al. Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med 1997;3(2):222-225.
17. Richter J, Wagner U, Kononen J et al. High-throughput tissue microarray analysis of cyclin E gene amplification and overexpression in urinary bladder cancer. Am J Pathol 2000;157(3):787-794.
18. Sui L, Dong Y, Ohno M et al. Implication of malignancy and prognosis of p27 (kip1), Cyclin E, and Cdk2 expression in epithelial ovarian tumors. Gynecol Oncol 2001;83(1):56-63.
19. Gros P, Ben Neriah YB, Croop JM et al. Isolation and expression of a complementary DNA that confers multidrug resistance. Nature 1986;323(6090):728- 731.
20. Koike K, Kawabe T, Tanaka T et al. A canalicular multispecific organic anion transporter (cMOAT) antisense cDNA enhances drug sensitivity in human hepatic cancer cells. Cancer Res 1997;57(24):5475-5479.
21. Cole SP, Chanda ER, Dicke FP et al. NonP-glycoprotein-mediated multidrug resistance in a small cell lung cancer cell line: Evidence for decreased susceptibility to drug-induced DNA damage and reduced levels of topoisomerase II. Cancer Res 1991;51(13):3345-3352.
22. DeVore RF, Corbett AH, Osheroff N. Phosphorylation of topoisomerase II by casein kinase II and protein kinase C: Effects on enzyme-mediated DNA cleavage/religation and sensitivity to the antineoplastic drugs etoposide and 4′-(9-acridinylamino) methane-sulfon-m-anisidide. Cancer Res 1992;52(8):2156-2161.
23. Takano H, Kohno K, Ono M et al. Increased phosphorylation of DNA topoisomerase II in etoposide-resistant mutants of human cancer KB cells. Cancer Res 1991;51(15):3951-3957.
24. Feldhoff PW, Mirski SE, Cole SP et al. Altered subcellular distribution of topoisomerase II alpha in a drug-resistant human small cell lung cancer cell line. Cancer Res 1994;54(3):756-762.
25. Mirski SE, Cole SP. Cytoplasmic localization of a mutant M (r) 160, 000 topoisomerase II alpha is associated with the loss of putative bipartite nuclear localization signals in a drug-resistant human lung cancer cell line. Cancer Res 1995;55(10):2129-2134.
26. Harker WG, Slade DL, Parr RL et al. Selective use of an alternative stop codon and polyadenylation signal within intron sequences leads to a truncated topoisomerase II alpha messenger RNA and protein in human HL-60 leukemia cells selected for resistance to mitoxantrone. Cancer Res 1995;55(21):4962-4971.
27. Wessel I, Jensen PB, Falck J et al. Loss of amino acids 1490Lys-Ser-Lys1492 in the COOH-terminal region of topoisomerase IIalpha in human small cell lung cancer cells selected for resistance to etoposide results in an extranuclear enzyme localization. Cancer Res 1997;57(20):4451-4454.
28. Rubin E, Halt W. Anthracyclines and DNA Intercalators/ Epipodophyllotoxins/Camptothecins/DNA Topoisomerases. In: Kufe DW, Pollock RE, Weichselbaum RR, Bast RC, Gansler TS, Holland JF, Frei E, eds. Cancer Medicine 6. Vol 1. Hamilton: BC Decker, 2003:783.
29. Fenselau C, Kan MN, Rao SS et al. Identification of aldophosphamide as a metabolite of cyclophosphamide in vitro and in vivo in humans. Cancer Res 1977;37(8 Pt 1):2538-2543.
30. Colvin M. Alkylating agents and platinum antitumor compounds. In: Kufe DW, Pollock RE, Weichselbaum RR, Bast RC, Gansler TS, Holland JF, Frei E, eds. Cancer Medicine 6. Vol 1. Hamilton: BC Decker, 2003:762.
31. Colvin M, Russo JE, Hilton J et al. Enzymatic mechanisms of resistance to alkylating agents in tumor cells and normal tissues. Adv Enzyme Regul 1988;27:211-221.
32. Hilton J. Role of aldehyde dehydrogenase in cyclophosphamide-resistant L1210 leukemia. Cancer Res 1984;44(11):5156-5160.
33. Koelling TM, Yeager AM, Hilton J et al. Development and characterization of a cyclophosphamide-resistant subline of acute myeloid leukemia in the Lewis x Brown Norway hybrid rat. Blood 1990;76(6):1209-1213.
34. Parsons PG, Lean J, Kable EP et al. Relationships between resistance to cross-linking agents and glutathione metabolism, aldehyde dehydrogenase isozymes and adenovirus replication in human tumour cell lines. Biochem Pharmacol 1990;40(12):2641-2649.
35. Rekha GK, Sreerama L, Sladek NE. Intrinsic cellular resistance to oxazaphosphorines exhibited by a human colon carcinoma cell line expressing relatively large amounts of a class-3 aldehyde dehydrogenase. Biochem Pharmacol 1994;48(10):1943-1952.
36. Sreerama L, Sladek NE. Identification of a methylcholanthrene-induced aldehyde dehydrogenase in a human breast adenocarcinoma cell line exhibiting oxazaphosphorine-specific acquired resistance. Cancer Res 1994;54(8):2176-2185.
37. Buller AL, Clapper ML, Tew KD. Glutathione S-transferases in nitrogen mustard-resistant and-sensitive cell lines. Mol Pharmacol 1987;31(6):575-578.
38. Nakagawa K, Saijo N, Tsuchida S et al. Glutathione-S-transferase pi as a determinant of drug resistance in transfectant cell lines. J Biol Chem 1990;265(8):4296-4301.
39. Pallante SL, Lisek CA, Dulik DM et al. Glutathione conjugates. Immobilized enzyme synthesis and characterization by fast atom bombardment mass spectrometry. Drug Metab Dispos 1986;14(3):313-318.
40. Puchalski RB, Fahl WE. Expression of recombinant glutathione S-transferase pi, Ya, or Yb1 confers resistance to alkylating agents. Proc Natl Acad Sci USA 1990;87(7):2443-2447.
41. Tew KD, Bomber AM, Hoffman SJ. Ethacrynic acid and piriprost as enhancers of cytotoxicity in drug resistant and sensitive cell lines. Cancer Res 1988;48(13):3622-3625.
42. O'Connor PM, Ferris DK, White GA et al. Relationships between cdc2 kinase, DNA cross-linking, and cell cycle perturbations induced by nitrogen mustard. Cell Growth Differ 1992;3(1):43-52.
43. Mulkins MA, Heidelberger C. Biochemical characterization of fluoropyrimidine-resistant murine leukemic cell lines. Cancer Res 1982;42(3):965-973. (Pubitemid 12141204)
44. Mulkins MA, Heidelberger C. Isolation of fluoropyrimidine-resistant murine leukemic cell lines by one-step mutation and selection. Cancer Res 1982;42(3):956-964. (Pubitemid 12141203)
45. Berger SH, Hakala MT. Relationship of dUMP and free FdUMP pools to inhibition of thymidylate synthase by 5-fluorouracil. Mol Pharmacol 1984;25(2):303-309.
46. Houghton JA, Houghton PJ. Elucidation of pathways of 5-fluorouracil metabolism in xenografts of human colorectal adenocarcinoma. Eur J Cancer Clin Oncol 1983;19(6):807-815.
47. Kufe DW, Major PP, Egan EM et al. 5-Fluoro-2'-deoxyuridine incorporation in L1210 DNA. J Biol Chem 1981;256(17):8885-8888.
48. Ingraham HA, Tseng BY, Goulian M. Mechanism for exclusion of 5-fluorouracil from DNA. Cancer Res 1980;40(4):998-1001.
49. Morikawa K, Fan D, Denkins YM et al. Mechanisms of combined effects of gamma-interferon and 5-fluorouracil on human colon cancers implanted into nude mice. Cancer Res 1989;49(4):799-805.
50. Jiang W, Lu Z, He Y et al. Dihydropyrimidine dehydrogenase activity in hepatocellular carcinoma: Implication in 5-fluorouracil-based chemotherapy. Clin Cancer Res 1997;3(3):395-399.
51. Etienne MC, Cheradame S, Fischel JL et al. Response to fluorouracil therapy in cancer patients: The role of tumoral dihydropyrimidine dehydrogenase activity. J Clin Oncol 1995;13(7):1663-1670.
52. Bapat AR, Zarow C, Danenberg PV. Human leukemic cells resistant to 5-fluoro-2'-deoxyuridine contain a thymidylate synthetase with lower affinity for nucleotides. J Biol Chem 1983;258(7):4130-4136.
53. Berger SH, Jenh CH, Johnson LF et al. Thymidylate synthase overproduction and gene amplification in fluorodeoxyuridine-resistant human cells. Mol Pharmacol 1985;28(5):461-467.
54. Aschele C, Sobrero A, Faderan MA et al. Novel mechanism (s) of resistance to 5-fluorouracil in human colon cancer (HCT-8) sublines following exposure to two different clinically relevant dose schedules. Cancer Res 1992;52(7):1855-1864.
55. Pizzorno G, Handschumacher RE. Effect of clinically modeled regimens on the growth response and development of resistance in human colon carcinoma cell lines. Biochem Pharmacol 1995;49(4):559-565.
56. Sobrero AF, Aschele C, Guglielmi AP et al. Synergism and lack of cross-resistance between short-term and continuous exposure to fluorouracil in human colon adenocarcinoma cells. J Natl Cancer Inst 1993;85(23):1937-1944.
57. Pizzorno G, Diasio R, Cheng Y. Pyrimidine and Purine Antimetabolites. In: Kufe DW, Pollock RE, Weichselbaum RR, Bast RC, Gansler TS, Holland JF, Frei E, eds. Cancer Medicine 6. Vol 1. Hamilton: BC Decker, 2003:748.
58. Curt GA, Jolivet J, Carney DN et al. Determinants of the sensitivity of human small-cell lung cancer cell lines to methotrexate. J Clin Invest 1985;76(4):1323-1329.
59. Li WW, Waltham M, Tong W et al. Increased activity of gamma-glutamyl hydrolase in human sarcoma cell lines: A novel mechanism of intrinsic resistance to methotrexate (MTX). Adv Exp Med Biol 1993;338:635-638.
60. Longo GS, Gorlick R, Tong WP et al. Disparate affinities of antifolates for folylpolyglutamate synthetase from human leukemia cells. Blood 1997;90(3):1241-1245.
61. Li WW, Lin JT, Tong WP et al. Mechanisms of natural resistance to antifolates in human soft tissue sarcomas. Cancer Res 1992;52(6):1434-1438.
62. Longo GS, Gorlick R, Tong WP et al. gamma-Glutamyl hydrolase and folylpolyglutamate synthetase activities predict polyglutamylation of methotrexate in acute leukemias. Oncol Res 1997;9(5):259-263.
63. Guo W, Healey JH, Meyers PA et al. Mechanisms of methotrexate resistance in osteosarcoma. Clin Cancer Res 1999;5(3):621-627.
64. Zhao R, Assaraf YG, Goldman ID. A mutated murine reduced folate carrier (RFC1) with increased affinity for folic acid, decreased affinity for methotrexate, and an obligatory anion requirement for transport function. J Biol Chem 1998;273(30):19065-19071.
65. Li W, Fan J, Hochhauser D et al. Lack of functional retinoblastoma protein mediates increased resistance to antimetabolites in human sarcoma cell lines. Proc Natl Acad Sci USA 1995;92(22):10436-10440.
66. Li W, Fan J, Banerjee D et al. Overexpression of p21 (waf1) decreases G2-M arrest and apoptosis induced by paclitaxel in human sarcoma cells lacking both p53 and functional Rb protein. Mol Pharmacol 1999;55(6):1088-1093.
67. Fan J, Bertino JR. Functional roles of E2F in cell cycle regulation. Oncogene 1997;14(10):1191-1200.
68. Alt FW, Kellems RE, Bertino JR et al. Selective multiplication of dihydrofolate reductase genes in methotrexate-resistant variants of cultured murine cells 1978. Biotechnology 1992;24:397-410.
69. Carman MD, Schornagel JH, Rivest RS et al. Resistance to methotrexate due to gene amplification in a patient with acute leukemia. J Clin Oncol 1984;2(1):16-20.
70. Cowan KH, Goldsmith ME, Levine RM et al. Dihydrofolate reductase gene amplification and possible rearrangement in estrogen-responsive methotrexate-resistant human breast cancer cells. J Biol Chem 1982;257(24):15079-15086.
71. Curt GA, Carney DN, Cowan KH et al. Unstable methotrexate resistance in human small-cell carcinoma associated with double minute chromosomes. N Engl J Med 1983;308(4):199-202.
72. Fischer GA. Increased levels of folic acid reductase as a mechanism of resistance to amethopterin in leukemic cells. Biochem Pharmacol 1961;7:75-77.
73. Horns Jr RC, Dower WJ, Schimke RT. Gene amplification in a leukemic patient treated with methotrexate. J Clin Oncol 1984;2(1):2-7.
74. Srimatkandada S, Medina WD, Cashmore AR et al. Amplification and organization of dihydrofolate reductase genes in a human leukemic cell line, K-562, resistant to methotrexate. Biochemistry 1983;22(25):5774-5781.
75. Dedhar S, Hartley D, Fitz-Gibbons D et al. Heterogeneity in the specific activity and methotrexate sensitivity of dihydrofolate reductase from blast cells of acute myelogenous leukemia patients. J Clin Oncol 1985;3(11):1545-1552.
76. Domin BA, Cheng YC, Hakala MT. Properties of dihydrofolate reductase from a methotrexate-resistant subline of human KB cells and comparison with enzyme from KB parent cells and mouse S180 AT/3000 cells. Mol Pharmacol 1982;21(1):231-238.
77. Flintoff WF, Essani K. Methotrexate-resistant Chinese hamster ovary cells contain a dihydrofolate reductase with an altered affinity for methotrexate. Biochemistry 1980;19(18):4321-4327.
78. Goldie JH, Dedhar S, Krystal G. Properties of a methotrexate-insensitive variant of dihydrofolate reductase derived from methotrexate-resistant L5178Y cells. J Biol Chem 1981;256(22):11629-11635.
79. Melera PW, Davide JP, Oen H. Antifolate-resistant Chinese hamster cells. Molecular basis for the biochemical and structural heterogeneity among dihydrofolate reductases produced by drug-sensitive and drug-resistant cell lines. J Biol Chem 1988;263(4):1978-1990.
80. Gorlick R, Goker E, Trippett T et al. Defective transport is a common mechanism of acquired methotrexate resistance in acute lymphocytic leukemia and is associated with decreased reduced folate carrier expression. Blood 1997;89(3):1013-1018.
81. Rowinsky E. Microtubule-targeting natural products. In: Kufe DW, Pollock RE, Weichselbaum RR, Bast RC, Gansler TS, Holland JF, Frei E, eds. Cancer Medicine 6. Vol 1. Hamilton: BC Decker, 2003:799.
82. Jordan MA, Toso RJ, Thrower D et al. Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc Natl Acad Sci USA 1993;90(20):9552-9556.
83. Dumontet C, Sikic BI. Mechanisms of action of and resistance to antitubulin agents: Microtubule dynamics, drug transport, and cell death. J Clin Oncol 1999;17(3):1061-1070.
84. Torres K, Horwitz SB. Mechanisms of Taxol-induced cell death are concentration dependent. Cancer Res 1998;58(16):3620-3626.
85. Wang LG, Liu XM, Kreis W et al. The effect of antimicrotubule agents on signal transduction pathways of apoptosis: A review. Cancer Chemother Pharmacol 1999;44(5):355-361.
86. Huisman C, Ferreira CG, Broker LE et al. Paclitaxel triggers cell death primarily via caspase-independent routes in the nonsmall cell lung cancer cell line NCI-H460. Clin Cancer Res 2002;8(2):596-606.
87. Horwitz SB, Cohen D, Rao S et al. Taxol: Mechanisms of action and resistance. J Natl Cancer Inst Monogr 1993; (15):55-61.
88. Cabral F, Wible L, Brenner S et al. Taxol-requiring mutant of Chinese hamster ovary cells with impaired mitotic spindle assembly. J Cell Biol 1983;97(1):30-39.
89. Cabral FR. Isolation of Chinese hamster ovary cell mutants requiring the continuous presence of taxol for cell division. J Cell Biol 1983;97(1):22-29.
90. Kavallaris M, Kuo DY, Burkhart CA et al. Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. J Clin Invest 1997;100(5):1282-1293.
91. Nicoletti MI, Valoti G, Giannakakou P et al. Expression of beta-tubulin isotypes in human ovarian carcinoma xenografts and in a sub-panel of human cancer cell lines from the NCI-Anticancer Drug Screen: Correlation with sensitivity to microtubule active agents. Clin Cancer Res 2001;7(9):2912-2922.
92. Ranganathan S, Benetatos CA, Colarusso PJ et al. Altered beta-tubulin isotype expression in paclitaxel-resistant human prostate carcinoma cells. Br J Cancer 1998;77(4):562-566.
93. Dubik D, Dembinski TC, Shiu RP. Stimulation of c-myc oncogene expression associated with estrogen-induced proliferation of human breast cancer cells. Cancer Res 1987;47(24 Pt 1):6517-6521.
94. Dubik D, Shiu RP. Mechanism of estrogen activation of c-myc oncogene expression. Oncogene 1992;7(8):1587-1594.
95. Murphy LJ, Murphy LC, Friesen HG. Estrogen induction of N-myc and c-myc proto-oncogene expression in the rat uterus. Endocrinology 1987;120(5):1882- 1888.
96. Prall OW, Sarcevic B, Musgrove EA et al. Estrogen-induced activation of Cdk4 and Cdk2 during G1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-Cdk2. J Biol Chem 1997;272(16):10882-10894.
97. Altucci L, Addeo R, Cicatiello L et al. 17beta-Estradiol induces cyclin D1 gene transcription, p36D1-p34cdk4 complex activation and p105Rb phosphorylation during mitogenic stimulation of G (1)-arrested human breast cancer cells. Oncogene 1996;12(11):2315-2324.
98. Planas-Silva MD, Weinberg RA. Estrogen-dependent cyclin E-cdk2 activation through p21 redistribution. Mol Cell Biol 1997;17(7):4059-4069.
99. *Cdk2. J Biol Chem 2001;276(48):45433-45442.
100. Osborne CK, Shou J, Massarweh S et al. Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clin Cancer Res 2005;11(2 Pt 2):865s-870s. (Pubitemid 40111098)
101. Razandi M, Alton G, Pedram A et al. Identification of a structural determinant necessary for the localization and function of estrogen receptor alpha at the plasma membrane. Mol Cell Biol 2003;23(5):1633-1646.
102. McKenna NJ, Lanz RB, O'Malley BW. Nuclear receptor coregulators: Cellular and molecular biology. Endocr Rev 1999;20(3):321-344.
103. Osborne CK, Zhao H, Fuqua SA. Selective estrogen receptor modulators: Structure, function, and clinical use. J Clin Oncol 2000;18(17):3172-3186.
104. Parker MG. Steroid and related receptors. Curr Opin Cell Biol 1993;5(3):499-504.
105. Shou J, Massarweh S, Osborne CK et al. Mechanisms of tamoxifen resistance: Increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 2004;96(12):926-935.
106. Kato S, Endoh H, Masuhiro Y et al. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 1995;270(5241):1491-1494.
107. Font de Mora J, Brown M. AIB1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor. Mol Cell Biol 2000;20(14):5041-5047.
108. Nicholson RI, McClelland RA, Robertson JF et al. Involvement of steroid hormone and growth factor cross-talk in endocrine response in breast cancer. Endocr Relat Cancer 1999;6(3):373-387.
109. Osborne CK, Bardou V, Hopp TA et al. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst 2003;95(5):353-361.
110. Smith CL, Nawaz Z, O'Malley BW. Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. Mol Endocrinol 1997;11(6):657-666.
111. Buzdar A, Harvey H. Aromatase Inhibitors. In: Kufe DW, Pollock RE, Weichselbaum RR, Bast RC, Gansler TS, Holland JF, Frei E, eds. Cancer Medicine 6. Vol 1. Hamilton: BC Decker, 2003:947.
112. Ellis MJ, Coop A, Singh B et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1-and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: Evidence from a phase III randomized trial. J Clin Oncol 2001;19(18):3808-3816.
113. Howell A, Cuzick J, Baum M et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005;365(9453):60-62.
114. Buzdar A, Harvey H. Aromatase Inhibitors. In: Kufe DW, Pollock RE, Weichselbaum RR, Bast RC, Gansler TS, Holland JF, Frei E, eds. Cancer Medicine 6. Vol 1. Hamilton: BC Decker, 2003:957.
115. Yu D, Hung MC. Overexpression of ErbB2 in cancer and ErbB2-targeting strategies. Oncogene 2000;19(53):6115-6121.
116. Nagata Y, Lan KH, Zhou X et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004;6(2):117-127.
117. Dieras V, Fumoleau P, Romieu G et al. Randomized parallel study of doxorubicin plus paclitaxel and doxorubicin plus cyclophosphamide as neoadjuvant treatment of patients with breast cancer. J Clin Oncol 2004;22(24):4958-4965.
118. Buzdar AU, Singletary SE, Theriault RL et al. Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. J Clin Oncol 1999;17(11):3412-3417.
119. Paridaens R, Dirix L, Lohrisch C et al. Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer. Ann Oncol 2003;14(9):1391-1398.
120. Nabholtz JM, Buzdar A, Pollak M et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: Results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 2000;18(22):3758-3767.
121. Milla-Santos A, Milla L, Portella J et al. Anastrozole versus tamoxifen as first-line therapy in postmenopausal patients with hormone-dependent advanced breast cancer: A prospective, randomized, phase III study. Am J Clin Oncol 2003;26(3):317-322.
122. Mouridsen H, Gershanovich M, Sun Y et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: Analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 2003;21(11):2101-2109.
123. Eiermann W, Paepke S, Appfelstaedt J et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study. Ann Oncol 2001;12(11):1527-1532.
124. Bonneterre J, Thurlimann B, Robertson JF et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: Results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol 2000;18(22):3748-3757.
125. Vogel CL, Cobleigh MA, Tripathy D et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20(3):719-726.
126. Norbury C, Nurse P. Animal cell cycles and their control. Annu Rev Biochem 1992;61:441-470.
127. Hartwell LH, Weinert TA. Checkpoints: Controls that ensure the order of cell cycle events. Science 1989;246(4930):629-634.
128. Pardee AB. A restriction point for control of normal animal cell proliferation. Proc Natl Acad Sci USA 1974;71(4):1286-1290.
129. Evans T, Rosenthal ET, Youngblom J et al. Cyclin: A protein specified by maternal mRNA in sea urchin eggs that is destroyed at each cleavage division. Cell 1983;33(2):389-396.
130. Pines J. Cyclins: Wheels within wheels. Cell Growth Differ 1991;2(6):305-310.
131. Ohtsubo M, Theodoras AM, Schumacher J et al. Human cyclin E, a nuclear protein essential for the G1-to-S phase transition. Mol Cell Biol 1995;15(5):2612-2624.
132. Keyomarsi K, Herliczek TW. The role of cyclin E in cell proliferation, development and cancer. Prog Cell Cycle Res 1997;3:171-191.
133. Zhang HS, Gavin M, Dahiya A et al. Exit from G1 and S phase of the cell cycle is regulated by repressor complexes containing HDAC-Rb-hSWI/SNF and Rb-hSWI/SNF. Cell 2000;101(1):79-89.
134. Montagnoli A, Fiore F, Eytan E et al. Ubiquitination of p27 is regulated by Cdk-dependent phosphorylation and trimeric complex formation. Genes Dev 1999;13(9):1181-1189.
135. Perez-Roger I, Kim SH, Griffiths B et al. Cyclins D1 and D2 mediate myc-induced proliferation via sequestration of p27 (Kip1) and p21 (Cip1). Embo J 1999;18(19):5310-5320.
136. Alevizopoulos K, Vlach J, Hennecke S et al. Cyclin E and c-Myc promote cell proliferation in the presence of p16INK4a and of hypophosphorylated retinoblastoma family proteins. Embo J 1997;16(17):5322-5333.
137. Cassia R, Moreno-Bueno G, Rodriguez-Perales S et al. Cyclin E gene (CCNE) amplification and hCDC4 mutations in endometrial carcinoma. J Pathol 2003;201(4):589-595.
138. Schraml P, Bucher C, Bissig H et al. Cyclin E overexpression and amplification in human tumours. J Pathol 2003;200(3):375-382.
139. Strohmaier H, Spruck CH, Kaiser P et al. Human F-box protein hCdc4 targets cyclin E for proteolysis and is mutated in a breast cancer cell line. Nature 2001;413(6853):316-322.
140. Rajagopalan H, Jallepalli PV, Rago C et al. Inactivation of hCDC4 can cause chromosomal instability. Nature 2004;428(6978):77-81.
141. Bloom J, Pagano M. Deregulated degradation of the cdk inhibitor p27 and malignant transformation. Semin Cancer Biol 2003;13(1):41-47.
142. Koepp DM, Schaefer LK, Ye X et al. Phosphorylation-dependent ubiquitination of cyclin E by the SCFFbw7 ubiquitin ligase. Science 2001;294(5540):173-177.
143. Harwell RM, Porter DC, Danes C et al. Processing of cyclin E differs between normal and tumor breast cells. Cancer Res 2000;60(2):481-489.
144. Akli S, Zheng PJ, Multani AS et al. Tumor-specific low molecular weight forms of cyclin E induce genomic instability and resistance to p21, p27, and antiestrogens in breast cancer. Cancer Res 2004;64(9):3198-3208.
145. Furstenthal L, Kaiser BK, Swanson C et al. Cyclin E uses Cdc6 as a chromatin-associated receptor required for DNA replication. J Cell Biol 2001;152(6):1267-1278.
146. Ma T, Van Tine BA, Wei Y et al. Cell cycle-regulated phosphorylation of p220 (NPAT) by cyclin E/Cdk2 in Cajal bodies promotes histone gene transcription. Genes Dev 2000;14(18):2298-2313.
147. Zhao J, Kennedy BK, Lawrence BD et al. NPAT links cyclin E-Cdk2 to the regulation of replication-dependent histone gene transcription. Genes Dev 2000;14(18):2283-2297.
148. Fisk HA, Winey M. The mouse Mps1p-like kinase regulates centrosome duplication. Cell 2001;106(1):95-104.
149. Okuda M, Horn HF, Tarapore P et al. Nucleophosmin/B23 is a target of CDK2/cyclin E in centrosome duplication. Cell 2000;103(1):127-140.
150. Shanahan F, Seghezzi W, Parry D et al. Cyclin E associates with BAF155 and BRG1, components of the mammalian SWI-SNF complex, and alters the ability of BRG1 to induce growth arrest. Mol Cell Biol 1999;19(2):1460-1469.
151. Wang C, Chua K, Seghezzi W et al. Phosphorylation of spliceosomal protein SAP 155 coupled with splicing catalysis. Genes Dev 1998;12(10):1409-1414.
152. Seghezzi W, Chua K, Shanahan F et al. Cyclin E associates with components of the premRNA splicing machinery in mammalian cells. Mol Cell Biol 1998;18(8):4526-4536.
153. Hara E, Hall M, Peters G. Cdk2-dependent phosphorylation of Id2 modulates activity of E2A-related transcription factors. Embo J 1997;16(2):332-342.
154. Deed RW, Hara E, Atherton GT et al. Regulation of Id3 cell cycle function by Cdk-2-dependent phosphorylation. Mol Cell Biol 1997;17(12):6815-6821.
155. Ohtsubo M, Roberts JM. Cyclin-dependent regulation of G1 in mammalian fibroblasts. Science 1993;259(5103):1908-1912.
156. Akli S, Keyomarsi K. Cyclin E and its low molecular weight forms in human cancer and as targets for cancer therapy. Cancer Biol Ther 2003;2(4 Suppl 1): S38-47.
157. Park JW. Liposome-based drug delivery in breast cancer treatment. Breast Cancer Res 2002;4(3):95-99.
158. Carlson BA, Dubay MM, Sausville EA et al. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Cancer Res 1996;56(13):2973-2978.
159. Losiewicz MD, Carlson BA, Kaur G et al. Potent inhibition of CDC2 kinase activity by the flavonoid L86-8275. Biochem Biophys Res Commun 1994;201(2):589-595.
160. Gray NS, Wodicka L, Thunnissen AM et al. Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science 1998;281(5376):533-538.
161. Senderowicz AM, Headlee D, Stinson SF et al. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J Clin Oncol 1998;16(9):2986-2999.
162. Thomas JP, Tutsch KD, Cleary JF et al. Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol. Cancer Chemother Pharmacol 2002;50(6):465-472.
163. Schiller JH, Harrington D, Belani CP et al. Comparison of four chemotherapy regimens for advanced nonsmall-cell lung cancer. N Engl J Med 2002;346(2):92-98.
164. Shapiro GI, Supko JG, Patterson A et al. A phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV nonsmall cell lung cancer. Clin Cancer Res 2001;7(6):1590-1599.
165. Kris MG, Natale RB, Herbst RS et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with nonsmall cell lung cancer: A randomized trial. Jama 2003;290(16):2149- 2158.
166. Meijer L, Borgne A, Mulner O et al. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur J Biochem 1997;243(1-2): 527-536.
167. McClue SJ, Blake D, Clarke R et al. In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine). Int J Cancer 2002;102(5):463-468.
168. Benson C, White J, Twelves C et al. A phase I trial of the oral cyclin dependent kinase inhibitor CYC202 in patients with advanced malignancy. Chicago, Il: Paper presented at: Annual Meeting of the American Society of Clinical Oncology, 2003.
169. Pierga J, Faiver S, Vera K. A phase I and pharmacokinetic (PK) trial of CYC202, a novel oral cyclin-dependent kinase (CDK) inhibitor, in patients (pts) with advanced solid tumors. Chicago, Il: Paper presented at: Annual Meeting of the American Society of Clinical Oncology, 2003.
170. Kim KS, Kimball SD, Misra RN et al. Discovery of aminothiazole inhibitors of cyclin-dependent kinase 2: Synthesis, X-ray crystallographic analysis, and biological activities. J Med Chem 2002;45(18):3905-3927.
171. Shapiro G, Lewis N, Bai S et al. A phase I study to determine the safety and pharmacokinetics (PK) of BMS-387032. Chicago, Il: Paper presented at: Annual Meeting of the American Society of Clinical Oncology, 2003.
172. McCormick J, Gadgeel M, Helmke W et al. Phase I study of BMS-387032, a
173. Jones S, Burris H, Kies M et al. A phase I study to determine the safety and pharmacokinetics (PK) of BMS-387032 given intravenously every three weeks in patients with metastatic refractory solid tumors. Chicago, Il: Paper presented at: Annual Meeting of the American Society of Clinical Oncology, 2003.
174. Akinaga S, Nomura K, Gomi K et al. Effect of UCN-01, a selective inhibitor of protein kinase C, on the cell-cycle distribution of human epidermoid carcinoma, A431 cells. Cancer Chemother Pharmacol 1994;33(4):273-280.
175. Akiyama T, Yoshida T, Tsujita T et al. G1 phase accumulation induced by UCN-01 is associated with dephosphorylation of Rb and CDK2 proteins as well as induction of CDK inhibitor p21/Cip1/WAF1/Sdi1 in p53-mutated human epidermoid carcinoma A431 cells. Cancer Res 1997;57(8):1495-1501.
176. Akiyama T, Shimizu M, Okabe M et al. Differential effects of UCN-01, staurosporine and CGP 41 251 on cell cycle progression and CDC2/cyclin B1 regulation in A431 cells synchronized at M phase by nocodazole. Anticancer Drugs 1999;10(1):67-78.
177. Chen X, Lowe M, Keyomarsi K. UCN-01-mediated G1 arrest in normal but not tumor breast cells is pRb-dependent and p53-independent. Oncogene 1999;18(41):5691-5702.
178. Kawakami K, Futami H, Takahara J et al. UCN-01, 7-hydroxyl-staurosporine, inhibits kinase activity of cyclin-dependent kinases and reduces the phosphorylation of the retinoblastoma susceptibility gene product in A549 human lung cancer cell line. Biochem Biophys Res Commun 1996;219(3):778-783.
179. Seynaeve CM, Stetler-Stevenson M, Sebers S et al. Cell cycle arrest and growth inhibition by the protein kinase antagonist UCN-01 in human breast carcinoma cells. Cancer Res 1993;53(9):2081-2086.
180. Shimizu E, Zhao MR, Nakanishi H et al. Differing effects of staurosporine and UCN-01 on RB protein phosphorylation and expression of lung cancer cell lines. Oncology 1996;53(6):494-504.
181. Usuda J, Saijo N, Fukuoka K et al. Molecular determinants of UCN-01-induced growth inhibition in human lung cancer cells. Int J Cancer 2000;85(2):275-280.
182. Wang Q, Fan S, Eastman A et al. UCN-01: A potent abrogator of G2 checkpoint function in cancer cells with disrupted p53. J Natl Cancer Inst 1996;88(14):956-965.
183. Busby EC, Leistritz DF, Abraham RT et al. The radiosensitizing agent 7-hydroxystaurosporine (UCN-01) inhibits the DNA damage checkpoint kinase hChk1. Cancer Res 2000;60(8):2108-2112.
184. Graves PR, Yu L, Schwarz JK et al. The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01. J Biol Chem 2000;275(8):5600-5605.
185. Sarkaria JN, Busby EC, Tibbetts RS et al. Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine. Cancer Res 1999;59(17):4375-4382.
186. Sato S, Fujita N, Tsuruo T. Interference with PDK1-Akt survival signaling pathway by UCN-01 (7-hydroxystaurosporine). Oncogene 2002;21(11):1727-1738.
187. Testa JR, Bellacosa A. AKT plays a central role in tumorigenesis. Proc Natl Acad Sci USA 2001;98(20):10983-10985.
188. Sausville EA, Arbuck SG, Messmann R et al. Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms. J Clin Oncol 2001;19(8):2319-2333.
189. Senderowicz A, Headlee D, Lush R et al. Phase I trial of infusional UCN-01, a novel protein kinase inhibitor, in patients with refractory neoplasms. Amsterdam, Holland: Paper presented at: 10th National Cancer Institute-European Organization fro Research on Treatment of Cancer Symposium, 1998.
190. Shao RG, Cao CX, Shimizu T et al. Abrogation of an S-phase checkpoint and potentiation of camptothecin cytotoxicity by 7-hydroxystaurosporine (UCN-01) in human cancer cell lines, possibly influenced by p53 function. Cancer Res 1997;57(18):4029-4035.
191. Jones CB, Clements MK, Wasi S et al. Enhancement of camptothecin-induced cytotoxicity with UCN-01 in breast cancer cells: Abrogation of S/G (2) arrest. Cancer Chemother Pharmacol 2000;45(3):252-258.
192. Hsueh CT, Kelsen D, Schwartz GK. UCN-01 suppresses thymidylate synthase gene expression and enhances 5-fluorouracil-induced apoptosis in a sequence-dependent manner. Clin Cancer Res 1998;4(9):2201-2206.
193. Bunch RT, Eastman A. Enhancement of cisplatin-induced cytotoxicity by 7-hydroxystaurosporine (UCN-01), a new G2-checkpoint inhibitor. Clin Cancer Res 1996;2(5):791-797.
194. Garcia HH, Brar GA, Nguyen DH et al. Indole-3-carbinol (I3C) inhibits cyclin-dependent kinase-2 function in human breast cancer cells by regulating the size distribution, associated cyclin E forms, and subcellular localization of the CDK2 protein complex. J Biol Chem 2005;280(10):8756-8764.
195. Chen X, Danes C, Lowe M et al. Activation of the estrogen-signaling pathway by p21 (WAF1/CIP1) in estrogen receptor-negative breast cancer cells. J Natl Cancer Inst 2000;92(17):1403-1413.
196. Barboule N, Chadebech P, Baldin V et al. Involvement of p21 in mitotic exit after paclitaxel treatment in MCF-7 breast adenocarcinoma cell line. Oncogene 1997;15(23):2867-2875.
197. Yu D, Jing T, Liu B et al. Overexpression of ErbB2 blocks Taxol-induced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2 kinase. Mol Cell 1998;2(5):581-591.
198. Bacus SS, Yarden Y, Oren M et al. Neu differentiation factor (Heregulin) activates a p53-dependent pathway in cancer cells. Oncogene 1996;12(12):2535- 2547.
199. Sugiyama K, Shimizu M, Akiyama T et al. Combined effect of navelbine with medroxyprogesterone acetate against human breast carcinoma MCF-7 cells in vitro. Br J Cancer 1998;77(11):1737-1743.
200. Rao S, Porter DC, Chen X et al. Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase. Proc Natl Acad Sci USA 1999;96(14):7797-7802.